Cargando…

Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform

BACKGROUND: There are an estimated 200,000 to 400,000 cases of visceral leishmaniasis (VL) annually. A variety of factors are taken into account when considering the best therapeutic options to cure a patient and reduce the risk of resistance, including geographical area, malnourishment and HIV coin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bush, Jacob T., Wasunna, Monique, Alves, Fabiana, Alvar, Jorge, Olliaro, Piero L., Otieno, Michael, Sibley, Carol Hopkins, Strub Wourgaft, Nathalie, Guerin, Philippe J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600407/ https://www.ncbi.nlm.nih.gov/pubmed/28873394 http://dx.doi.org/10.1371/journal.pntd.0005781

Ejemplares similares

Visceral Leishmaniasis: New Health Tools Are Needed
por: Hailu, Asrat, et al.
Publicado: (2005)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans
por: Dahal, Prabin, et al.
Publicado: (2021)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis
por: Dahal, Prabin, et al.
Publicado: (2021)

Methodology of Clinical Trials Aimed at Assessing Interventions for Cutaneous Leishmaniasis
por: Olliaro, Piero, et al.
Publicado: (2013)

Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India
por: Goyal, Vishal, et al.
Publicado: (2019)

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis
por: Singh-Phulgenda, Sauman, et al.
Publicado: (2021)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
por: Mondal, Dinesh, et al.
Publicado: (2019)

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India
por: Goyal, Vishal, et al.
Publicado: (2018)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent
por: Meheus, Filip, et al.
Publicado: (2010)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial
por: Mbui, Jane, et al.
Publicado: (2019)

Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent – A Systematic Literature Review
por: Hirve, Siddhivinayak, et al.
Publicado: (2016)

Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: A proposal for neglected tropical diseases
por: Couderc-Pétry, Monique, et al.
Publicado: (2020)

Eco-epidemiology of visceral leishmaniasis in Ethiopia
por: Gadisa, Endalamaw, et al.
Publicado: (2015)

Validation of Two Rapid Diagnostic Tests for Visceral Leishmaniasis in Kenya
por: Mbui, Jane, et al.
Publicado: (2013)

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
por: Kip, Anke E, et al.
Publicado: (2021)

How Far Are We from Visceral Leishmaniasis Elimination in Bangladesh? An Assessment of Epidemiological Surveillance Data
por: Chowdhury, Rajib, et al.
Publicado: (2014)

Visceral Leishmaniasis and HIV Coinfection in the Mediterranean Region
por: Monge-Maillo, Begoña, et al.
Publicado: (2014)

Epidemiology of Visceral Leishmaniasis in Georgia
por: Babuadze, Giorgi, et al.
Publicado: (2014)

The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform
por: Maguire, Brittany J., et al.
Publicado: (2021)

Visceral Leishmaniasis Outbreak in South Sudan 2009–2012: Epidemiological Assessment and Impact of a Multisectoral Response
por: Abubakar, Abdinasir, et al.
Publicado: (2014)

Eliminating visceral leishmaniasis in South Asia: the road ahead
por: Rijal, Suman, et al.
Publicado: (2019)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Social determinants of visceral leishmaniasis elimination in Eastern Africa
por: Alvar, Jorge, et al.
Publicado: (2023)

Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context
por: Molina, Ricardo, et al.
Publicado: (2020)

Towards elimination of visceral leishmaniasis in the Indian subcontinent—Translating research to practice to public health
por: Hirve, Siddhivinayak, et al.
Publicado: (2017)

Evaluating drug resistance in visceral leishmaniasis: the challenges
por: HENDRICKX, S, et al.
Publicado: (2018)

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh
por: Mondal, Dinesh, et al.
Publicado: (2019)

Complexities of Assessing the Disease Burden Attributable to Leishmaniasis
por: Bern, Caryn, et al.
Publicado: (2008)

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
por: Verrest, Luka, et al.
Publicado: (2021)

Long-Term Efficacy of Insecticidal Wall Painting for Controlling Visceral Leishmaniasis Vectors in Bangladesh
por: Alim, Abdul, et al.
Publicado: (2023)

Sustaining visceral leishmaniasis elimination in Bangladesh – Could a policy brief help?
por: Fitzpatrick, Alyssa, et al.
Publicado: (2017)

Intervention Packages for Early Visceral Leishmaniasis Case Detection and Sandfly Control in Bangladesh: A Comparative Analysis
por: Huda, M. Mamun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jl1dfnd00gleue00p5olh69pcd